



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/11, 15/63, 15/64	A1	(11) International Publication Number: WO 98/28417 (43) International Publication Date: 2 July 1998 (02.07.98)
(21) International Application Number: PCT/US97/24236 (22) International Filing Date: 20 December 1997 (20.12.97) (30) Priority Data: 60/033,816 23 December 1996 (23.12.96) US (71) Applicant (for all designated States except US): GENE-CELL [US/US]; 1010 Hercules Avenue, Houston, TX 77058 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): DAVIS, Brian [US/US]; 2107 Barrington Point Drive, League City, TX 77573 (US). YAO, Aqiong [US/US]; 100 Market #58, Galveston, TX 77550 (US). (74) Agent: MAYFIELD, Denise, L.; Vinson & Elkins, L.L.P., Suite 2300, 1001 Fannin Street, Houston, TX 77002-6760 (US).		(81) Designated States: AL; AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: NUCLEIC ACID CONSTRUCTS AND USES THEREOF FOR DIRECT NUCLEIC ACID INCORPORATION INTO CELLS		
(57) Abstract <p>Disclosed are compositions for incorporating nucleic acid into a cell. Transgene constructs that include a desired nucleic acid sequence of interest may be injected into a cell together with a protein to provide site specific or random incorporation of the nucleic acid sequence into the chromosomal DNA of the cell. The transgene construct and the protein are included in the described compositions together, with the protein facilitating the incorporation of the nucleic acid sequence of interest within the transgene construct, directly into the nucleic acid of a cell in a site-specific manner. In other embodiments, the compositions include a transgene construct and an expression construct, the expression construct including a nucleic acid sequence that encodes an enzyme capable of facilitating the incorporation of the transgene sequence of interest into a cell. The invention further includes methods for incorporating a foreign nucleic acid into a cell employing a microinjection method. In particular embodiments, the method may be employed to introduce foreign nucleic acid into cells that grow in a non-adherent state. In these applications, the cells are immobilized onto a substrate surface that includes an adherent molecule, such as fibronectin. Alternatively, the cells may be stabilized sufficiently to permit microinjection using holding pipettes or through the stimulation of the cells themselves to express molecules on their surface which bind chemical entities included <u>at</u> the surface of a culture plate.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NUCLEIC ACID CONSTRUCTS AND USES THEREOF FOR DIRECT NUCLEIC ACID INCORPORATION INTO CELLS

This application claims the benefit of U. S. Provisional Application No: 60/033,816,
5 filed 23 December 1996.

TECHNICAL FIELD

The present invention relates to the technical field of nucleic acid incorporation into cells. The invention further relates to the technical field of gene therapy, as techniques
10 described herein may be employed as part of a gene therapy protocol, wherein a number of genetic defects related to particular gene defects may be corrected and/or treated.

BACKGROUND ART

Hematopoietic stem cell gene therapy offers significant promise for treatment of
15 various diseases. At least three requirements must be satisfied for long-term efficacy of stem cell gene therapy: 1) direct genetic modification of hematopoietic stem cells, 2) maintenance of transgene sequences in stem cells and their progeny, and 3) long-term transgene expression in the appropriate cells.

The stem cell compartment, likely to be heterogeneous, consists of rare, long-lived,
20 predominantly quiescent cells that are capable of both long-term reconstitution of the complete hematopoietic system in transplanted hosts and some degree of self-renewal [Ogawa, 1993]. Since stem cells require several months to establish hematopoiesis following transplantation, they must be supplemented with a larger number of short-term reconstituting cells for rapid engraftment [Jones *et al.*, 1995]. For most gene therapy applications, it will
25 likely be sufficient to modify only the stem cells - rapid reconstitution of progenitor-derived unmarked cells would be followed by long term engraftment with genetically marked stem-derived cells.

The introduced therapeutic gene(s) must be successfully transmitted from the stem cell to progeny cells requiring the genetic correction. Since currently available episomal
30 plasmids generally demonstrate only a moderate level of persistence in the absence of selective pressure and artificial human chromosomes await further development [Harrington *et al.*, 1997], chromosomal integration is presently the most viable option for gene maintenance.

Correction of genetic deficiencies will require that the therapeutic gene be expressed in the appropriate cells for the life of the patient. Genetic therapy for the lysosomal storage diseases, irrespective of whether they involve soluble or membrane-bound enzymes, will require life-long production of sufficient levels of the correct enzyme in monocyte/macrophages. Production of insufficient amounts of enzyme will generally lead to redevelopment of disease.

It is well recognized that major problems currently beset the stem cell gene therapy field [Orkin and Motulsky, 1996]. Since the development of retroviral transduction technology in the mid 1980s, this has been a standard gene delivery technique for hematopoietic cells. However, retroviral transduction of primitive hematopoietic cells has revealed significant difficulties in satisfying requirements 1) and 3) identified above. It has been clearly demonstrated in laboratory studies, animal models, and now clinical trials that the presently employed retroviral vectors rarely transduce the quiescent human hematopoietic stem cell, thus failing to fulfill the first requirement [Miller *et al.*, 1990; Kohn *et al.*, 1995; Dick *et al.*, 1996; Dick, 1996; Nolte *et al.*, 1996]. This is evidenced by the extremely low frequency (0.1-1.0%) of gene marked peripheral leukocytes several months after transplant in human trials - indicating stem cell transduction rates of less than or equal to 1% [Kohn *et al.*, 1995; Brenner *et al.*, 1993]. The only early human hematopoietic cells efficiently transduced are cycling progenitors and long term culture initiating cells (LTCICs) [Cassel *et al.*, 1995; Hughes *et al.*, 1989], generally capable of sustaining high levels of blood cell production in vivo only for a finite period (i.e. approximately 2-12 months) - before they are replaced by the progeny of unmodified stem cells. These disappointing results with human stem cells contrast sharply with the efficient retroviral transduction of both stem cells and progenitors routinely demonstrated in the mouse system. Three distinct factors are likely to be responsible for the failure to directly transduce human stem cells: a) the quiescent nature of the stem cells, b) the absence of the appropriate receptors for retroviral envelope on the stem cells [Crooks and Kohn, 1995], and c) that the retroviral transduction conditions, requiring in vitro cycling of stem cells, may actually cause significant loss of stem cell function [Nolte *et al.*, 1996]. Although various techniques are being attempted to overcome these difficulties, the simultaneous solution of all three is not guaranteed. For example, although lentivirus-based vectors may be capable of transducing some non-cycling cells [Naldini *et al.*, 1996], the failure of HIV-1 to infect quiescent primary CD4⁺ T-lymphocytes

[Zack *et al.*, 1990] (i.e. generating only a partial, labile reverse transcript) suggests that the G₀ stem cells may yet prove resistant to transduction. Thus, significant effort is now being devoted to the evaluation of Adeno-associated virus (AAV) vectors for stem cell transduction. However, there is controversy and uncertainty regarding AAV's ability to transduce and stably integrate into quiescent primary cell genomes [Podsakoff *et al.*, 1994; Halbert *et al.*, 1995; Russell *et al.*, 1994].

Even if these gene introduction issues can be solved, significant problems remain in satisfying the third requirement for long-term, cell type-specific expression. For example, the expression of retrovirus-transduced transgenes is frequently silenced in the progeny of transduced human or primate progenitors, and even in progeny of transduced mouse stem/progenitors [Akkina *et al.*, 1994; Challita and Kohn, 1994; Lu *et al.*, 1994]. Furthermore, even in those cells demonstrating some expression, there is significant variability in the level of expression from cell to cell [Sadelain *et al.*, 1995]. As a consequence of this dysregulated expression, hematopoietic cells, although genetically modified with corrective genes, may not efficiently display the corrected phenotype. Interestingly, these same features of dysregulated expression were also observed in the early transgenic mouse expression studies [Kollias and Grosveld, 1992]. Subsequent studies demonstrated that long-term, position-independent, copy number-dependent, cell-type specific expression required not only strong promoter/enhancer elements, but also: a) sufficient genomic sequences to dominantly confer the appropriate chromatin configuration (i.e. an open chromatin conformation in expressing cells) e.g. locus control region (LCR)-like elements [Kollias and Grosveld, 1992; Caterina *et al.*, 1994; Talbot *et al.*, 1990] and perhaps additional elements to shield the integrated sequences from the effects of neighboring chromatin, and b) sufficient intron/exon structure and sequences for high level expression [Brinster *et al.*, 1988]. Unfortunately, the strict packaging requirements for retrovirus vectors (maximum of 8 kb inserted sequences), and the even stricter requirements for AAV vectors (maximum of 4 kb) [Miller *et al.*, 1994], may preclude inclusion of sufficient regulatory sequences and/or intron/exon structure for therapeutic applications requiring even moderately regulated therapeutic gene expression. For example, recent studies examining inclusion of LCR sequences in retroviral and AAV vectors showed extreme variation in the level of transgene expression from cell to cell [Sadelain *et al.*, 1995; Einerhand *et al.*, 1995]. It is also possible that strong splicing signals (i.e. intron/exon

structure) or cryptic splicing signals in transgene sequences will interfere with retroviral packaging of the desired unspliced full-length construct [Einerhand *et al.*, 1995].

The inability of the current technologies to efficiently transduce stem cells is a major deficiency, thus warranting distinct and innovative approaches for transduction.

5 Electroporation and liposome-mediated transfection technologies have been reported for gene delivery to hematopoietic cells. However, these methods are associated with inherent features that raise questions regarding their appropriateness for stem cell gene therapy. These features include a) the inability of either method to transfect a significant percentage of enriched primary primitive hematopoietic cells of mouse and man [Toneguzzo
10 and Keating, 1986; Harrison *et al.*, 1996], b) significant variation from cell to cell in the copy number of DNA molecules transfected, and c) transient retention of the transgene with only a small minority of cells (1-in 10^4 - 10^5 for electroporation) becoming stably transduced [Philip *et al.*, 1994]. Although less information is available on the recently developed particle-mediated bombardment technique for gene delivery, a recent primary T-cell
15 transfection study reported a 2-10% transfection rate 5 days post bombardment with 1.6 micron gold particle/DNA complexes [Woffendin *et al.*, 1994]. Based on the present inventor's studies with needle sizes in the size range of these particles, stem cell damage would be unacceptably high. It is also not clear that the available non-viral transduction methods would permit co-delivery of proteins with DNA - required for anticipated future
20 applications.

Clinical applications of gene therapy require that therapeutic genes delivered to quiescent stem cells persist both in the self-renewing stem cells and in their maturing/differentiating progeny. Irrespective of the gene transfer method, it is crucial to understand how stem cells, and particularly quiescent stem cells, handle and integrate foreign
25 DNA sequences. Very little is known regarding the fate of DNA (e.g. whether it is integrated into chromosomal DNA) introduced into the nuclei of stem cells, and particularly quiescent stem cells. Viral transduction of primary or quiescent cells may be blocked at several points before integration (e.g. incomplete reverse transcription or transport to the nucleus for retroviruses [Miller *et al.*, 1990; Zack *et al.*, 1990], incomplete conversion of single stranded
30 DNA to double stranded proviral DNA for AAV [Russell *et al.*, 1994]). This has made it very difficult, in the context of the normal AAV or retrovirus life cycle, to focus specifically on the transgene integration process in stem cells. The literature has not revealed any

evidence that integration of microinjected sequences is dependent on cycling. The ability of wild-type HIV-1 to stably transduce quiescent macrophages [Weinberg *et al.*, 1991] and cell-cycle arrested CD4⁺ HeLa or T lymphoid cells [Lewis *et al.*, 1992] indicates that integration in non-proliferating cells is, in fact, possible. Integration of HIV-1 proviral DNA is mediated by the Integrase enzyme. Some studies indicate that integration of M-MuLV sequences need not occur during mitosis [Roe *et al.*, 1993]; in addition, both chromatin and naked DNA can serve as integration targets in vitro [Pryciak *et al.*, 1992]. Although there is little question regarding the ability of wild-type HIV-1 to integrate in quiescent cells, this has not yet been conclusively demonstrated for HIV-1 based vectors. HIV-1 based vectors have been reported to be capable of establishing a stable transduction intermediate in quiescent Rat 208F fibroblasts [Naldini *et al.*, 1996]. Cells recruited from quiescence even 8 days after original infection had stable transduction frequencies equal to 50% of those infected while in a cycling state.

A need continues to exist in the medical arts for a method that provides for an improved cell viability upon introduction of genetic material into a cell.

DISCLOSURE OF THE INVENTION

The present invention in one aspect relates to the delivery of transgenes, or transgenes complexed with integration enzymes, directly to the nuclei of cells. Such has resulted in the increased incorporation of the transgene into the chromosomal DNA of the cell. In some embodiments, delivery is targeted to primitive cord blood stem cells. This technology will overcome the obstacles to transduction encountered by retroviruses and AAV vectors. The present invention proposes the use of Integrase-mediated integration of appropriately LTR-flanked transgenes in quiescent cells. When considered together with the propensity of retroviral DNAs to integrate into the chromatin of active genes, this indicates to the present inventor that integration is enhanced in the presence of open transcriptionally active chromatin. That is, AAV vectors and Type C retrovirus had not prior to this time been reported to be capable of accomplishing integration readily into quiescent cells.

Generally stated, the present invention in some aspects provides for a method of introducing nucleic acid into the chromosomal nucleic acid of a cell employing a particularly defined composition that includes a protein and a transgene construct. The transgene

construct may be further defined as comprising a nucleic acid sequence of interest flanked by a terminal fragment of a long terminal repeat sequence (LTR), such as a retroviral LTR. The terminal fragment may include a length of about 10 to about 300 nucleotides, or between about 10 to about 250 nucleotides, or in even further defined embodiments, between about 20 to about 200 nucleotides, in length.

In some embodiments, the protein is defined as an enzyme, such as a retroviral integrase. The protein in other embodiments of the invention may be further defined as a fusion protein, such as an enzyme fused to a nucleic acid binding protein. In yet other embodiments, delivery is particularly targeted to primitive cord blood stem cells. The ability to deliver larger regions of DNA (containing required regulatory elements and significant intron/exon structure) than those packageable in retrovirus or AAV virions will avert the dysregulated expression and silencing frequently observed in the progeny of transduced stem/progenitor cells.

The present invention provides improved compositions containing integrase for delivery of genetic material to cells. In particular embodiments, the cells are hematopoietic stem cells. Microinjection has only rarely been used for primary hematopoietic cells¹³. This has largely been due to the inability to effectively immobilize hematopoietic cells for microinjection, as well as the significant damage caused by standard microinjection needles to the much smaller hematopoietic cells. The present invention reduces both these technical difficulties. In this regard, the invention in one aspect, provides a novel method for temporary immobilization of primitive hematopoietic cells (CD34⁺, CD34⁺/CD38⁻, CD34⁺/CD38⁻/Thy-1^{lo}) allowing cells to be rapidly microinjected and then released for subsequent culture and/or transplantation. Fine micropipets with 0.05 - 0.5 micron tip diameter, or 0.12 - 0.2 micron tip outer diameter (O.D.), capable of controllable minimal flow rates, and causing minimal injury to microinjected cells (6-8 micron diameter) are employed in some embodiments of the invention employing the nucleic acid injection preparation described herein. One advantage of the herein described method is that microinjection of minute quantities of either DNA and/or proteins suffice for injection of numerous cells. Until recent years microinjection was not a reasonable option for stem cell modification due to inadequate characterization of the human stem cell phenotype. But with recent identification of enriched populations of primitive human hematopoietic cells likely to include stem cells (e.g. CD34⁺/lin⁻/Thy-1^{lo}¹⁴, CD34⁺/CD45Ra^{-lo}/CD71^{-lo}/Thy-1^{lo}¹⁵, CD34⁺/CD38⁻¹⁶, CD34⁺/c-kit^{lo}¹⁷, CD34⁺/CD38⁻/CD33⁻/CD19⁻/CD45Ra⁻/c-kit⁺¹⁸), the number

of cells requiring genetic modification has reached a point where gene modification at a single cell level may be a viable alternative.

This innovative approach, focused on modifying one cell at a time as well as multiple cell injection, including the automated injection techniques, provides an economically feasible approach to current cell modification and gene therapy approaches.

Primitive cord blood stem cells will be more efficient than delivery of same with retroviruses and AAV vectors. It is further contemplated that larger regions of DNA, such as those containing required regulatory elements and significant intron/exon structure, than those deliverable by retroviruses or AAV virions will be deliverable by the present microinjection method and will avert the dysregulated expression and silencing frequently observed in the progeny of transduced stem cells.

In some embodiments, the methods include the use of one or more integrases as the particular protein enzyme. By way of example, these integrases include AAV Rep⁷⁸ or retroviral integrases such as M-MuLV, HIV-1, SIV, FeLV, RSV, AMV, or EIAV. These integrases may be in the form of expressed recombinant proteins (expressed either in bacteria, insect cells, or eukaryotic cells) and be either wild-type integrase protein or modified in their amino acid sequence. Modification of the amino acid sequences may occur via several techniques, such as: a) by fusion with additional amino acids to facilitate purification (e.g. histidine tagged, Glutathione S-Transferase (GST) tagged, Maltose Binding Protein (MBP) tagged), b) by fusion with amino acid sequences which provide for binding to specific DNA sequences (DNA binding protein) – and therefore site-preferred or site-specific targeting of integration to specific sites within chromosomal DNA), c) by site specific mutation in the integrase amino acid sequence to provide for greater integrase protein solubility, to provide for increased efficiency in performing the integration reaction, etc.

Although *in vitro* integration can be accomplished at some frequency with Δ LTR_{HIV-1} sequences and Integrase_{HIV-1} alone, inclusion of particular cellular proteins (e.g. the human homolog of yeast transcription factor SNF5 [Kalpana *et al.*, 1994] and DNA bending protein HMG1 [Farnet and Bushman, 1997]) may also be used to even further increase the efficiency of the incorporation and integration. Increased integration efficiency may therefore be achieved by inclusion of such cellular proteins in the DNA/Integrase mixture to be delivered to cells.

The present invention further provides for the co-delivery with the transgene construct and retroviral integrase other viral proteins that are normally present in the retroviral pre-integration complex. For example, M-MuLV gag proteins are present in the M-MuLV pre-integration complex, potentially increasing the efficiency of the integration reaction.

5

BRIEF DESCRIPTION OF DRAWINGS

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

10

FIG. 1 Introduction of transgenes into cells together with specific enzymes designed to facilitate integration. Constructs flanked by the termini of retroviral long terminal repeats (LTR) will be co-delivered with retroviral integrase. This approach could apply to any retrovirus (e.g. a lenti-virus such as Human Immunodeficiency Virus type 1 or a type C retrovirus such as Moloney Murine Leukemia Virus). Constructs flanked by the AAV inverted terminal repeats (ITR) will be co-delivered with AAV Rep⁷⁸. Although this schematic shows introduction of both the transgene construct and the integration enzyme by microinjection, both transgene and enzyme could potentially be delivered by other means, such as electroporation, liposome-mediated gene transfer, or particle-mediated bombardment. In addition, it is possible that the integration enzyme would not need be delivered as protein. Rather, it could be co-delivered as a DNA expression construct together with the transgene targeted for integration. If only the transgene, and not the integration enzyme expression construct, was flanked with LTR or ITR sequences, this would facilitate integration of only the desired transgene.

20
25

FIG. 2. Strategies for integration. Simple introduction of the transgene and regulatory elements into the cell, when resulting in integration, should result in integration at random sites, with possible head-to-tail concatamers. Simple addition of the AAV ITR sequences are expected to provide increased rates of integration. High frequencies of integration have been observed for rep⁻ AAV vectors, which like this construct, only contain ITR sequences and no Rep⁷⁸. The precise structure of the rep⁻ AAV DNA prior to integration may either exist as a linear duplex flanked by ITRs, or be circularized in the nucleus prior to integration. Hence, the present invention proposes that increased rates of integration may

30

result from circularization of the 2 ITR-containing construct. In the absence of the rep gene products the integrants generally show no specificity for the AAVS 1 region of Chromosome 19. Addition of Rep⁷⁸ protein (shown in the next construct) is expected to increase the preference of integration for Chromosome 19, since Rep⁷⁸ recognizes DNA sequences both in the AAV ITR and the Chromosome 19 AAVSI region. In the next construct, the gene construct is flanked by sequences derived from a retroviral LTR. For example, the only M-MuLV LTR sequences required for *in vitro* integration reactions are the extreme 10-12bp LTR termini. The M-MuLV viral enzyme Integrase interacts with these sequences to facilitate integration *in vitro* and *in vivo*. There appears to be no site specificity for integration of M-MuLV based vectors, although there is some preference with respect to nucleosomal conformation. Shown in the next part of the diagram is the interaction with the LTR sequences of a fusion protein between Integrase and a DNA binding protein. This DNA binding domain could either be derived from an existing DNA binding protein, or a novel protein could be designed and synthesized to have a high affinity for specific genomic DNA sequences. For example, it is possible that specific targeting of transgenes to the globin locus would facilitate their expression specifically in erythroid cells.

FIG. 3. Diagramed are the two fusion proteins expressed and purified in our laboratory to facilitate integration of microinjected DNA sequences. Shown above is a fusion between the maltose binding protein and the Rep⁷⁸ protein of AAV. This was expressed from an MBP-Rep⁷⁸ expression construct (Batchu *et al.*, 1995). The MBP-Rep⁷⁸ fusion protein, purified in the identical manner, was reported to exhibit *in vitro* binding to the AAV ITRs, endonuclease activity, and helicase activity. Should the MBP sequences interfere with integration activity (in the cell), they may be removed from Rep⁷⁸ by cleavage with factor Xa (a factor Xa cleavage site is present at the site of fusion between MBP and Rep⁷⁸). Shown below is a similar fusion between MBP and the integrase gene of M-MuLV. The M-MuLV integrase gene was cloned from a construct described in Jonsson *et al.*, (1993) – and cloned into the pMALc2 vector used for expression of MBP-Rep⁷⁸. However, the strategy described is not limited to MBP-fusion proteins in the practice of the present invention. It could equally well employ any expression and purification strategy – for example, GST-fusions, histidine-tagged expression and purification, baculovirus expression vs. *E. coli* expression, and expression in eukaryotic cells.

FIG. 4A and FIG. 4B. Purification of MBP-Rep⁷⁸ fusion protein. FIG. 4A: bacterial lysates from pMAL-Rep⁷⁸ transformed bacteria – grown either in the absence of IPTG, or

presence of IPTG (to induce MBP-Rep⁷⁸ expression). FIG. 4B: A new band of approximately 120 kD is present in the +IPTG lane. Bacteria grown in the presence of IPTG were sonicated, and the supernatant passed twice over an amylose column. MBP-Rep⁷⁸ was eluted from the column by addition of maltose. There is an additional co-purifying band, running at a somewhat lower molecular weight. [Batchu *et al.*, 1995] postulated that this may be a product of a favored proteolytic cleavage of the full length MBP-Rep⁷⁸ or due to a favored early termination product. By scanning the gel, the purity of this preparation is estimated to be 90-95%.

FIG. 5. Purification of MBP-Integrase fusion protein. An expression construct fusing the MBP sequences with the M-MuLV Integrase gene [Johnson *et al.*, 1993] was prepared. Sequencing of the expression construct confirmed the appropriate in-frame fusion. The MBP-Integrase protein expressed and purified similarly to that described in FIG. 4 above for MBP-Rep⁷⁸. Bacteria grown in the presence of IPTG were sonicated, and the supernatant passed once over an amylose column. A strong band running slightly slower than the 85 kD molecular weight marker is consistent with the estimated 88 kD fusion protein. The purity of this preparation is estimated to be in the range of 70-80%.

FIG 6. Sample constructs to be employed in assaying integration enzyme-mediated integration; prsGFP-MGMT contains both the humanized red shifted Green Fluorescent Protein gene (GFP; from Gibco BRL, pGREEN) and the human O⁶-methylguanine DNA methyltransferase gene. All transgenes in this and the following constructs are driven by the phosphoglycerate kinase (pgk) promoter sequences. This particular construct is flanked by rare enzyme sites (Fse I, Pac I, Asc I, Sfi I) to readily permit removal of bacterial plasmid sequences to obtain linearized transgene sequences only (by restriction enzyme digestion and, if necessary, eluting the correctly sized fragment from a preparative agarose gel). prsGFP-MGMT/ITR contains the AAV2 ITR sequences flanking the prsGFP-MGMT sequences. Again, linear sequences absent of bacterial plasmid sequences will be obtained by digestion with Fse I and Sfi I enzymes. It is also possible to obtain this construct in a circularized form by converting the Sfi I site to an Fse I site, digesting with Fse I, and religating to form a 2-ITR containing circle. Since this may be the appropriate substrate for AAV integration, this circularized construct may integrate more easily than the linearized, either in the absence or presence of Rep⁷⁸. The last construct consists of linearized rsGFP-MGMT/ Δ LTR obtained by PCR amplification with primers containing, at their 5' ends, 20 bases of sequence corresponding to HIV-1 LTR termini. PCR amplification was used to generate double

stranded linear constructs flanked by the appropriate HIV-1 termini. If the 20 bp of sequence are not sufficient for efficient integration, the strategy may be modified to include additional LTR sequences.

FIG 7. Generation of pgk-tk/ Δ LTR_{HIV-1}. Shown is the construct containing the herpesvirus type 1 thymidine kinase (tk) gene, together with the phosphoglycerate kinase (pgk) promoter. Also shown are SV40 splice donor/acceptor and polyadenylation sequences. PCR primers were designed to generate a 2.74 kbp linear fragment containing the pgk and tk sequences, spanned by the terminal sequences of the HIV-1 LTR. The primer (HIVU3; 36 bases) employed upstream of the Fse I site included 20 bases corresponding to the terminus of the U3 region (underlined) and 16 bases corresponding to sequences in the original pCMV β vector (5' ACTGGAAGGGCTAATTCACTGTTGGGAAGGGCGATC 3') (SEQ ID NO: 1). The primer (HIVU5; 35 bases) employed downstream of the Sfi site included 20 bases corresponding to the terminus of the U5 region (underlined) and 15 bases corresponding to sequences in pCMV β (5' ACTGCTAGAGATTTCCACACAGGAAACAGCTATG 3') (SEQ ID NO: 2). Amplified linear double stranded DNA was obtained after 30 cycles of PCR amplification employing Vent DNA polymerase (New England Biolabs). After PCR, the PCR product was extracted with chloroform, precipitated with sodium acetate and alcohol, resuspended in TE, subjected to electrophoresis in a 1% agarose gel, gel purified using a GeneClean kit (Bio 101), precipitated with sodium acetate and alcohol, resuspended in water, filtered through a 0.1 micron filter, and stored at -20 deg C until use.

FIG 8. pgk-tk/ITR. Shown is the pgk-tk construct, flanked by AAV ITRs to generate pgk-tk/ITR. Linearized ITR-flanked pgk-tk sequences are obtained by digestion with Fse I and Sfi I, and then gel purified to eliminate bacterial plasmid sequences, since bacterial plasmid sequences have been shown to interfere with gene expression in transgenic mice.

FIG 9. Generation of covalently closed circles for facilitating integration. cir-rsGFP-MGMT/ITR will be employed as a circular double-stranded DNA in some aspects of the present invention. A plasmid backbone containing the AAV ITRs has been constructed, and the rsGFP-MGMT sequences inserted between the Pac I and Asc I sites to generate prsGFP-MGMT/ITR. Linearized ITR-flanked rsGFP-MGMT sequences have been obtained as described above by digestion with Fse I and Sfi I. Circularized rsGFP-MGMT/ITR sequences, absent the plasmid backbone, will be generated as diagramed in Fig. 9. The Sfi

I site was converted in prsGFP-MGMT/ITR to create a second Fse I site. This will be linearized and the backbone plasmid sequences removed via Fse I digestion, religate to circularize at the Fse I site, and purified for circular molecules on an agarose gel prior to microinjection.

5

BEST MODES FOR CARRYING OUT THE INVENTION

The present invention in some embodiments provides a method for the transduction of hematopoietic stem cells (HSCs) and thus an alternative strategy for their direct genetic modification by: 1) direct delivery of DNA sequences into the nuclei of HSCs by microinjection; 2) integration of microinjected transgene sequences in the chromatin of HSCs and persistence of those sequences in the progeny of said HSCs; and 3) microinjection of sufficiently large (15-25 Kb) transgenic DNA constructs containing regulatory elements, such as promoters, enhancers and LCRs, and intron/exon structure necessary for appropriate long-term, cell type-specific expression of the introduced transgenes; and 4) microinjection of DNA/protein mixtures with the protein(s) included in the injection sample having gene targeting activities.

Genetically modified HSCs prepared according to the methods of the present invention can be employed for gene therapy applications once said modified HSCs have been delivered to humans for long-term reconstitution.

According to other embodiments of the present invention, hematopoietic stem cells that have been modified by microinjection of foreign material can be used to treat a variety of physiological disorders such as, by way of example and without limitation, AIDS, thalassemia, sickle cell anemia, and adenosine deaminase deficiency.

The physiological disorders contemplated within the invention will be responsive to gene therapy. By "responsive to gene therapy" is meant that a patient suffering from such disorder will enjoy a therapeutic or clinical benefit such as improved symptomatology or prognosis.

As indicated above, one aspect of the present invention relates to the use of modified HSCs, as cellular vehicles for gene transfer. The genes, or transgenes, can be any gene having clinical usefulness, for example, therapeutic or marker genes or genes correcting gene defects (e.g. mutant hemoglobin genes in thalassemia or sickle cell anemia) in blood cells. In some embodiments, the primary human cells are blood cells. The term "blood cells" as

used herein is meant to include all forms of blood cells as well as progenitors and precursors thereof, as hereinabove described.

Thus, in one embodiment, the invention is directed to a method of enhancing the therapeutic effects of HSCs, comprising: (i) microinjecting into the HSCs of a patient a DNA
5 segment encoding a product that enhances the therapeutic effects of the human primary cells; and (ii) introducing the genetically modified HSCs resulting from step (i) into the patient.

The DNA produces the agent in the patient's body, and, in accordance with such embodiment, the agent is expressed at the tissue site itself. Similarly, as hereinabove indicated, HSCs which are genetically engineered need not be targeted to a specific site and,
10 in accordance with the invention, such engineered HSCs and their progeny function as a systemic therapeutic; e.g., a desired therapeutic agent can be expressed and secreted from the cells systemically.

More specifically, there is provided a method of enhancing the therapeutic effects of HSCs that are infused in a patient, comprising: (i) microinjecting into the HSCs of a patient
15 a DNA segment encoding a product that enhances the therapeutic effects of the blood cells; and (ii) introducing cells resulting from step (i) into the patient.

The primary human blood cells which are the progeny of modified HSCs and which can be used in the present invention include, by way of example, leukocytes, granulocytes, monocytes, macrophages, lymphocytes, and erythroblasts. For example, stem cells from
20 thalassemic or sickle cell anemia clients that are genetically modified with the appropriate hemoglobin gene may give rise to genetically corrected red blood cells.

The DNA carried by the HSCs can be any DNA having clinical usefulness, for example, any DNA that directly or indirectly enhances the therapeutic effects of the cells. Alternatively, the DNA carried by the HSCs can be any DNA that allows the HSCs to exert
25 a therapeutic effect that the HSCs would not normally exert. Examples of suitable DNA, which can be used for genetically engineering, for example, blood cells, include those that encode cytokines such as tumor necrosis factor (TNF), interleukins (for example, interleukins 1-12), globin genes, DNA-repair genes, drug-resistance genes and HIV (Human Immunodeficiency Virus) resistance genes.

30 The DNA which is used for transducing the human cells can be one whose expression product is secreted from the cells. Alternatively, it may encode for gene products retained within the cell. The human cells can also be genetically engineered with DNA which functions as a marker, as hereinafter described in more detail.

In one aspect, the inserted genes are marker genes which permit determination of the traffic and survival of the transformed cells *in vivo*. Examples of such marker genes include the neomycin resistance (neoR) gene, multi-drug resistant gene, thymidine kinase gene, β -galactosidase, dihydrofolate reductase (DHFR) and chloramphenicol acetyl transferase.

5 The HSCs are genetically engineered *in vitro*. For example, cells may be removed from a patient and stem cells isolated; genetically engineered *in vitro* with DNA encoding the therapeutic agent, with such genetically engineered HSCs being readministered along with a pharmaceutically acceptable carrier to the patient. Such a treating procedure is sometimes referred to as an *ex vivo* treatment.

10 As part of a clinical treatment regiment for a patient having cancer or at risk of developing cancer, the progeny of the modified HSCs provide a population of primary human cells that express the product of the genetic foreign material microinjected into the parent HSCs.

The pharmaceutically acceptable carrier may be a liquid carrier (for example, a saline solution) or a solid carrier; e.g., an implant. In employing a liquid carrier, the engineered cells may be introduced parenterally, e.g., intravenously, sub-cutaneously, intramuscularly, intraperitoneally, or intralesionally.

The following abbreviations have been used in the preparation of this disclosure.

15 pCMV- β DNA plasmid expressing the β -gal reporter gene under control of the cytomegalovirus (CMV) promoter/enhancer sequences.

FITC-Dextran FITC coupled to dextran

25 CD34+CD38-Thy-1+ the CD38⁻Thy-1⁺ (actually Thy-1¹⁰) subpopulation of CD34⁺ cells isolated by FACS.

IMDM Iscove's Modified Dulbeccos Media.

30 The foregoing will be better understood with reference to the following examples which detail certain procedures according to the present invention. All references made to these examples are for the purposes of illustration. They are not to be considered limiting as to the scope and nature of the present invention.

EXAMPLE 1
DELIVERY OF FITC-DEXTRAN TO IMMOBILIZED CD34⁺ CELLS
Purification and Culturing of CD34⁺ CELLS

5 The CD34⁺ antigen, present on approximately 0.5-1.0% of mononuclear bone marrow and umbilical cord blood cells, marks measurable human hematopoietic stem and progenitor cells. Umbilical cord blood cells were obtained from normal human fetal deliveries, and mononuclear cells were purified by centrifugation over Ficoll-hypaque. CD34⁺ cells were isolated by immunomagnetic selection with the Miltenyi MiniMACS CD34 Multisort
10 Isolation Kit (involves (1) incubation of cells with anti-CD34 antibody coupled via dextran to immunomagnetic particles, (2) isolation of magnetically-labeled cells by passing through a column attached to a magnet, (3) release of cells from magnetic particles by cleavages with dextranase, (4) separation of cells from magnetic particles by passing through column attached to a magnet). Subsequent FACS analysis, with another anti-CD34 antibody
15 recognizing a different CD34 epitope, demonstrated that the cells were 90% pure for CD34 expressing cells. Purified cells were maintained overnight (18 hrs) in serum free medium (Iscoves Modified Dulbecco's Medium (IMDM, Gibco) supplemented with bovine serum albumin (2%, StemCell Technology), insulin (10 micrograms/ml), transferrin (200 microgram/ml, ICN), 2-mercaptoethanol (0.05 mM, Sigma), low-density lipoprotein (40
20 microgram/ml, Sigma), and pen-strep (100 units and 50 microgram/ml, respectively) containing 20 ng/ml human Flt-3 ligand (Peprotech), 20 ng/ml human Interleukin-3 (IL-3, Peprotech), and 20 ng/ml human Stem Cell Factor (SCF, Peprotech) [IMDM/F-3-S] at 37° C with 5% CO₂.

25 Preparation of Fibronectin-Coated Surface

A 6 mm glass cloning ring was attached via vaseline to a 35 mm tissue culture dish (Corning). The dish surface enclosed by the cloning ring was coated with fibronectin by adding 30-50 microliters of a 50 microgram/ml fibronectin solution (Boehringer Mannheim, #1051-407) in phosphate buffered saline (PBS, Sigma), and incubating overnight at 4 °C
30 (alternatively, can be for 45 min. at room temperature). Excess fibronectin-containing solution was removed from the cloning ring immediately prior to addition of cells.

Attachment of CD34⁺ Cells to Fibronectin-Coated Dish

After overnight culture, cells were prepared at a concentration of 8×10^4 cells/ml in IMDM/F-3-S. This cell-containing media (25 microliters containing approximately 2000 cells) was mixed with 25 microliters of media (IMDM) conditioned 2 days by the TS2/16.2.1 hybridoma cell line (ATCC #HB-243 which produces antibody reactive with Integrin beta, -human CD29). The 50 microliters of cell/antibody mixture was placed into a 6 mm glass cloning ring enclosing the fibronectin-coated surface. Cells, in the presence of antibody, were allowed to attach to fibronectin for greater than 30 min. at 37 °C in the presence of 5% CO₂. Subsequently, 1 ml of IMDM/F-3-S was added outside the cloning ring, and the 35 mm plate containing cells and cloning ring was spun at 600 rpm for 5 min (Beckman low-speed GS-6R centrifuge, swinging bucket rotor, brake off).

Microinjection of CD34⁺ Cells with FITC-Dextran

Fine glass microinjection needles were prepared from thin-walled borosilicate glass capillaries (Sutter, 1.2 mm O.D., 0.94 mm I.D.) with an automated pipet puller (Sutter, P-87, 3 mm box filament). Scanning Electron Transmission (SE) microscopy was used to determine the outer diameter of microinjection needles pulled with the identical program; O.D.s between 0.17 and .22 micron were obtained. FITC-dextran (150,000 M.W., Sigma) at a concentration of 0.25% (weight per volume) in 50 mM Hepes (pH 7.2/100 mM KCl/5 mM NaH₂PO₄) was passed through a 0.02 micron filter (World Precision Instruments) and centrifuged at high speed (10,000 rpm, IEC Centra-4b) before loading via an Eppendorf microloader into microinjection needles. Microinjections were performed manually with a Narishige micromanipulator mounted on an Olympus OMT-2 inverted microscope (with heated stage) with a 40x phase dry objective. Pressure for fluid delivery was provided by an SAS 10/2 Screw Actuated Air micro-injection/aspiration syringe. The cloning ring was removed immediately before microinjection. After flow of fluid from the needle was confirmed, 60 cells (in approximately 30-45 minutes) were microinjected with approximately 2-10 femtoliters of FITC-dextran. Although delivery of material was targeted for the nucleus, some material was delivered to the cytoplasm.

Monitoring and Subsequent Culture of Microinjected Cells

After microinjection, a larger cloning ring (8 mm diameter) was placed around the region of microinjected cells. Delivery of FITC-dextran to cells was monitored by

fluorescence microscopy with a Nikon Diaphot 300 inverted microscope with fluorescence attachment (FITC.). Both bright-field and fluorescence images can be captured and saved with a Hamamatsu chilled CCD camera and controller, Sony Trinitron monitor, frame grabber, and networked Gateway 486-25. Within 30 min after microinjection, approximately 35 FITC-positive cells (out of 60 total; 58-67%) were clearly identifiable. A significant number of the cells clearly showed nuclear localization of fluorescence; some showed both nuclear and cytoplasmic localization, and a small number showed only cytoplasmic fluorescence. Twenty-four hours post microinjection, 19 fluorescent cells (32%) were still visible; seventy-two hours post microinjection, 16 fluorescent cells (32%) were visible.

EXAMPLE 2

TRANSGENE CONSTRUCT

The present example is provided to demonstrate the utility of the present invention for providing transgene constructs that include a nucleic acid sequence encoding a gene of interest, such as a therapeutic gene, and the successful stable incorporation and expression of the therapeutic gene, in a cell. The gene may be any mammalian gene, or pharmacologically active fragment thereof, and particularly a human gene.

The present example describes a number of transgene constructs that express both the red shifted Green Fluorescent Protein (rsGFP) reporter gene and the human O⁶-methylguanine DNA methyltransferase (MGMT) gene. The MGMT gene is one that would provide chemotherapeutic agent resistance to cells, and hence would provide a desired and useful treatment for a patient exposed to chemotherapeutic agents. For example, such may include patients with cancer/tumors undergoing chemotherapy as part of an anti-cancer regimen.

Since the rsGFP reporter permits rapid and sensitive assessment of expression, it will permit a rapid determination of nuclear-specific gene delivery and transgene persistence. The human MGMT gene was chosen because MGMT transgene expression in mouse stem cells is sufficient to protect them from the toxic effects of alkylating agents such as BCNU. The present invention provides methods for targeted expression of MGMT in human stem cells, and further demonstrates the utility of the invention for *in vivo* enrichment of transduced stem cells.

In some embodiments, the invention provides a method for the stable transduction of primitive cord blood cells, and the preparation of immature cord blood populations enriched in SRC activity. Improved methods for stable integration frequency in cell co-injected with constructs flanked by HIV-1 LTR or AAV ITR sequences together with HIV-1 Integrase or AAV Rep⁷⁸ are also provided.

Four particular transgene constructs are defined in FIG. 6. All include MGMT.

EXAMPLE 3 HUMAN GENE THERAPY METHODS

The present example demonstrates the utility of the present invention for providing a gene therapy treatment for humans.

The number of stem cells that need be delivered to humans for long term reconstitution may be extrapolated from mouse, large animal, and human studies to permit a reasonable estimate. Since the genetic therapies under consideration will frequently be directed to children, these estimates are based on their smaller body weight. Although a significant number of unmarked, short-term reconstituting cells may be co-delivered to better facilitate rapid engraftment and survival, the focus here is on the much smaller number of gene-modified, long-term reconstituting stem cells. a) Three independent mouse studies have reported long-term reconstitution with as few as 20 marrow cells [Halbert *et al.*, 1995], 10 marrow cells [Russell *et al.*, 1994], or even 1 marrow cell (20% of mice reconstituting [Akkina *et al.*, 1994]). If direct scaling by weight alone is appropriate, an average reconstitution requirement of 5 cells for mice would extrapolate into approximately a 5,000 marrow cell requirement for a human child. b) In human marrow transplantation, the minimal dose typically delivered is 1×10^8 nucleated cells per kg body weight [Challita and Kohn, 1994], equivalent to 2.5×10^9 cells for a 25 kg child. Experimental data and modeling of feline hematopoiesis indicate that the stem cell frequency is approximately 1 in 1.7×10^6 marrow cells [Lu *et al.*, 1994]. If this same frequency holds for human marrow, delivery of 2.5×10^9 cells corresponds to delivery of 1450 stem cells. c) Children reconstitute with as little as 30 mls of transplanted cord blood, likely due to the significant proliferative potential of primitive hematopoietic cord blood cells [Sadelain *et al.*, 1995]. Assuming approximately $1.5 - 3 \times 10^8$ nucleated cells in this volume, with a stem cell frequency of 1 in 10^5 to 10^6 this translates into successful engraftment with as few as 150 -3,000 stem cells. d) Evidence from engraftment of human cord blood cells in NOD/SCID mice suggests a very close relationship

(if not equivalence) between NOD/SCID reconstituting cells (SRCs) and human stem cells. SRCs are present at a frequency of ~ 1 in 10^4 CD34⁺ cells [Kollias and Grosveld, 1992; Caterina *et al.*, 1994]. Thus, 30 mls of cord blood (with approximately 3×10^7 mononuclear cells, 1% of which are CD34⁺) contain approximately 30 SRCs. Even if the seeding efficiency of SRCs in NOD/SCID mice is only 10%, this translates into 300 SRCs. Thus, all four calculations suggest a number of stem cells in the range of about 150 to about 5000 would be useful as a treatment in the practice of the present invention. Successful reconstitution is affected by stem cell delivery and engraftment by short-term progenitors. It is possible therefore that the stem cell requirements are even less than those calculated in b) and c) above.

Although the present hematopoietic stem cell-oriented work has been with manual microinjection (100-200 injected cells/hr), the presently disclosed methods are expected to easily accommodate the higher-speed (300-600 cells/hr) automated injection. The automated microinjection system may well be adequate for clinical gene therapy applications. Computer automated systems, capable of 1500 cell injections per hour [Pepperkok *et al.*, 1988], may be employed to microinject a sufficient number of stem cells for transplantation (i.e. 1000-10,000 cells depending on the stable transduction frequency). Any significant *in vitro* or *in vivo* expansion of stem cells [Emerson, 1996], as well as together with selection for marked cells, would further decrease the number of microinjected stem cells required for engraftment.

EXAMPLE 4 DNA CONSTRUCTS AND GENE THERAPY

A significant fraction of corrected stem cells present *in vivo* may be accomplished by *in vitro* selection for marked stem cells prior to engraftment (so that only the successfully transduced cells are transplanted into the patient) and/or by subsequent *in vivo* selection for marked stem cells (to enrich for gene marked stem cells at the expense of endogenous, unmarked stem cells). This will generally require transduction of stem cells with two independently regulated genes present on the same DNA construct: the selectable gene targeted for expression in stem/progenitor cells and the therapeutic gene (e.g. ADA or globin) - targeted for expression in the required cell type. Genes potentially useful in *in vitro* selection of transduced stem cells include rsGFP or truncated nerve growth factor receptor

(tNGF-R). Transduction of stem cells with the human O⁶-methylguanine DNA methyltransferase (MGMT) gene will enable *in vivo* selection of surviving, marked stem cells by briefly treating patients with alkylating agents of the nitrosourea class (e.g. 1,3-bis (2-chloroethyl)-1-nitrosourea; BCNU). Whereas most anti-neoplastic drugs (e.g. Taxol) are toxic to cycling hematopoietic progenitors, sparing the quiescent hematopoietic stem cells, nitrosoureas, such as BCNU, also exert their DNA-damaging and toxic effects directly on the stem cells. MGMT, which removes O⁶-alkylguanine induced in DNA by various alkylating agents, is normally expressed at very low levels in hematopoietic stem/progenitor cells. However, when exogenously expressed in cells, MGMT confers cell resistance to BCNU, CCNU, dacarbazine, N-methyl-N'-nitro-N-nitrosoguanidine, temozolomide, and streptozotocin. For example, mice expressing MGMT in their stem cells were resistant to BCNU-induced hematosuppression [Maze *et al.*, 1996]. The human multiple drug resistance gene (MDR-1) has been proposed for *in vivo* selection of transduced stem cells. Human stem cells already constitutively express MDR-1 [Chudhary and Roninson, 1991]. Hence, the enrichment for transduced cells by MDR-1 resistant drugs (e.g. taxol) as employed in the practice of the present invention is expected to occur at the level of progenitors but not stem cells. As is true for any proposed *in vivo* selection (e.g. BCNU, taxol) for marked hematopoietic cells, drug toxicity for other organs and cells will be minimized. MGMT transgene expression, by itself, is expected to confer resistance in hematopoietic cells to agents such as BCNU employed in high-dose or repetitive chemotherapy for breast and other cancers [Maze *et al.*, 1996].

In one aspect, gene therapeutic applications of stem cell microinjection may include the following elements: Approximately $1-10 \times 10^3$ highly enriched stem cells will be obtained from cord blood, and will be temporarily immobilized. Microinjection of these cells will deliver a reproducible volume—containing DNA, and in some embodiments, also include integration enzyme(s)—such that 1-3 copies of the DNA are successfully integrated per cell. Microinjected DNAs of 15-25 kb in size, containing two independently regulated transgenes, will be integrated without rearrangement. One transgene, targeted for expression in stem cells, will provide for *in vitro* (e.g. rsGFP, or truncated nerve growth factor receptor; tNGF-R) or *in vivo* (e.g. MGMT) selection of transduced stem cells. The therapeutic transgene (e.g. ADA for ADA SCID, globin for hemoglobinopathies, MDR-1 for chemoresistance) will be targeted for expression in the appropriate hematopoietic cells. Microinjection would also be an appropriate method for eventual nuclear delivery of artificial human chromosomes and/or

episomal plasmids capable of persistent maintenance. In some embodiments, cell viabilities greater than 80% post microinjection and stable transduction frequencies greater than 25% are expected to be provided.

5

EXAMPLE 5
PURIFICATION AND BIOLOGICAL ASSAYS
OF PRIMITIVE CORD BLOOD CELLS

CD34⁺, CD34⁺/CD38⁻, and CD34⁺/CD38⁻/Thy-1^{lo} populations of cord blood cells are provided. CD34⁺ hematopoietic cells, representing approximately 0.5 - 1.0% of nucleated umbilical cord blood and bone marrow cells, comprise all measurable human stem/progenitor activity. The CD34⁺/CD38⁻ phenotype (approximately 5-10% of CD34⁺ cord blood cells) characterizes an even more primitive subpopulation. Cells capable of engrafting human hematopoiesis in the immunodeficient NOD/SCID mice—considered to be more primitive than LTCICs and colony forming cells—are present exclusively in the CD34⁺/CD38⁻ population [Dick *et al.*, 1996; Dick, 1996]. CD34⁺/CD38⁻ cord blood cells are highly enriched in the primitive CD34⁺/CD45Ra^{-lo}/CD71^{-lo} phenotype identified by Mayani *et al.* [Mayani *et al.*, 1993]. Their further demonstration—that the Thy-1^{lo} subset of CD34⁺/CD45Ra^{-lo}/CD71^{-lo} cells represents an even more primitive population of cells—is consistent with the characterization of human fetal liver stem cells as being CD34⁺/lin⁻/Thy-1^{lo}. The present inventors have observed that CD34⁺/CD38⁻/Thy-1^{lo} cells (approximately 10-25% of CD34⁺/CD38⁻ cells) are significantly more enriched than CD34⁺/CD38⁻/Thy-1⁻ cells in LTCICs that produce colony forming cells generating large numbers of progeny. Based on the above considerations, CD34⁺, CD34⁺/CD38⁻, and CD34⁺/CD38⁻/Thy-1^{lo} phenotypes represent increasingly enriched populations of human stem cells.

Protocols to purify and functionally assay these particular cell populations—to permit the microinjection and stable transduction assays—are thus to also be provided.

30

EXAMPLE 6
PURIFICATION OF CD34⁺/CD38⁻; AND
CD34⁺/CD38⁻/THY-1^{lo} CELLS

Umbilical cord blood cells were obtained on a weekly basis (2-4 samples per week; total of 100-250 mls) from normal deliveries at UTMB, and pooled mononuclear cells isolated by centrifugation over Ficoll-hypaque. CD34⁺ cells are isolated by immunomagnetic

selection with the Miltenyi MiniMACS CD34 Multisort Isolation Kit. Isolated cells are obtained free of attached magnetized particles (by cleaving the dextran antibody-particle linker with dextranase). Recovery was typically 70-90% of the expected CD34 cell number (100 mls of cord blood typically yields $1-2 \times 10^8$ mononuclear cells, with CD34 isolation giving $1-2 \times 10^6$ cells with 90-95% viability and 80-95% CD34 positivity). Fluorescence activated cell sorting (FACS) with a Becton-Dickinson FACS Vantage instrument is then employed to isolate specific CD34⁺ cell subpopulations. Cells satisfying the sort criteria are either bulk sorted into tubes or a pre-specified number are deposited into individual wells of a 96 well plate via an Automated cell deposition unit (ACDU). For purification of CD34⁺/CD38⁻ cells, the enriched CD34⁺ cells are stained with PerCP-CD34 and PE-CD38 antibodies, and cells satisfying both the CD34⁺/CD38⁻ and low side and forward scatter criteria are isolated. CD34⁺/CD38⁻ cells typically comprise approximately 5-10% of the total CD34⁺ cells; with an actual sort recovery rate of 50%, we yield approximately $2 - 5 \times 10^4$ CD34⁺/CD38⁻ cells per sort. Excellent purity of the sorted CD34⁺/CD38⁻ cells was obtained. The primitive nature of the sorted CD34⁺/CD38⁻ cells was substantiated by the vast majority of them exhibiting the CD45Ra^{-lo}/CD71^{-lo} phenotype. The CD34⁺/CD38⁻ population may in some instances subdivide into Thy-1^{lo} (approximately 10-25% of the CD34⁺/CD38⁻ cells) and Thy-1⁻ (approximately 75-90% of CD34⁺/CD38⁻ cells) subsets. Approximately $2-10 \times 10^3$ CD34⁺/CD38⁻/Thy-1^{lo} enriched cells can be typically recovered in such sorts. Such provides a method for enhancing a population of cells for primitive (CD34⁺/CD38⁻, CD34⁺/CD38⁻/Thy-1^{lo}) populations of cord blood cells to be used in the microinjection and functional assays.

25 EXAMPLE 7
EXPRESSION OF rsGFP BY MICROINJECTED
CD34⁺, CD34⁺/CD38⁻/THY-1^{lo} CELLS

Transient reporter gene expression in cells microinjected with DNA is demonstrated in the present example. The rsGFP reporter is the represented DNA employed. It permits rapid assessment of gene expression, without the need for additional antibody labeling or enzymatic assays.

Cells are isolated and attached to fibronectin. Cells are generally microinjected with about 100 to about 250 ng/microliter solution, in microinjection buffer, of plasmid DNA expressing the humanized rsGFP protein under control of the cytomegalovirus (CMV)

promoter/enhancer. Microinjection needles of 0.2 +/- 0.02 micron O.D. are presently employed. rsGFP expression is monitored by fluorescence microscopy using a filter set optimized for rsGFP detection. rsGFP expression in 10-15% of injected cells, 5-24 hours post injection was generally observed. Although this frequency gradually decreases with increasing time of culture and observation, expressing cells (and a smaller number of dividing, expressing cells) were observed as late as 4-5 days after microinjection. Since the FITC-dextran injection results suggest that approximately 30-50% of injected cells survive quantitative delivery of injected material (24 hrs post injection), then approximately 20-50% of successfully injected cells transiently expressed rsGFP 5-24 hours post injection. In general, the rsGFP-expressing cells appear to be in very good condition, with normal morphology. However, there are occasional expressing cells whose condition deteriorates with time. No significant difference in the expression frequency among CD34⁺, CD34⁺/CD38⁻, and CD34⁺/CD38⁻/Thy-1^{lo} populations was observed. This data provides dispositive evidence for transgene expression in primitive CD34⁺/CD38⁻/Thy-1^{lo} cells. Further studies will be required to elucidate the gradual decline in the number of rsGFP-expressing cells. However, this pattern is not unexpected since almost all expression should be from unintegrated DNA copies—and expression should decrease as the unintegrated copies become degraded.

20

EXAMPLE 8
EXPRESSION AND PURIFICATION OF AAV Rep⁷⁸
M-MuLV INTEGRASE PROTEINS

Integration of microinjected DNA sequences is facilitated in some aspects of the invention by flanking them with specific AAV (ITR) or M-MuLV (LTR) sequences, and coinjecting them with proteins (AAV Rep⁷⁸ or M-MuLV Integrase, respectively), which by interacting with these sequences, will enhance and/or facilitate their integration. Bacterially expressed and purified protein has been used in these studies. A fusion protein consisting of the maltose binding protein (MBP) fused to AAV Rep⁷⁸ has been expressed in bacteria. It has been purified to approximately 90-95% homogeneity by double passage over an amylose column (MBP-Rep⁷⁸ 120 kD, total protein obtained ~1 mg; Figure 4). The MBP-Rep⁷⁸ expression construct used is described in Batchu *et al.* (1995). The MBP-Rep⁷⁸ fusion protein, purified in the identical manner, was reported herein to exhibit *in vitro* binding to the AAV ITRs, endonuclease activity, and helicase activity [Batchu *et al.*, 1995]. The

present investigators purified material exhibits binding to the AAV ITR sequences. Additional experiments confirm that the binding of MBP-Rep⁷⁸ to AAV ITR sequences is sequence specific (i.e. minimal binding to control, irrelevant DNA sequences) and results in the expected endonucleolytic cleavage of the ITR hairpin structure. These data demonstrate that the purified MBP-Rep⁷⁸ protein has *in vitro* activity consistent with that of Rep⁷⁸ alone. It is therefore expected that it will be active in microinjected cells. Should the fused MBP sequences interfere with integration activity, they will be removed from Rep⁷⁸ by cleavage with factor Xa (a factor Xa cleavage site is present at the site of fusion between MBP and Rep⁷⁸). A similar construct for expression of an MBP-Integrase fusion protein has been generated in the present inventor's laboratory (the M-MuLV Integrase sequences described in Johnson *et al.*, (1993). Sequencing of the expression construct has confirmed the appropriate in-frame fusion. The fusion protein has already been over-expressed in bacteria and has already been purified to ~70-80% homogeneity by single passage over amylose (Fig. 5; MBP-Integrase 88 kD). Similar GST- and histidine-Integrase fusions have previously been shown to function in *in vitro* integration reactions. Again if MBP interferes with Integrase activity, MBP will be released by factor Xa cleavage. Alternatively, the GST-Integrase fusion protein will be expressed and purified [Dotan *et al.*, 1995]).

EXAMPLE 9 LINEARIZED LTR-DNA AND ITR-DNA CONSTRUCTS

For evaluation of integration strategies in hematopoietic stem cells, constructs will be employed that are capable of expressing both the red shifted Green Fluorescent Protein (rsGFP) reporter gene and the human MGMT gene. The rsGFP reporter gene in microinjection has been employed by the present investigators. It permits rapid assessment of transgene expression, without the need for additional antibody labeling or enzymatic assays. In addition, it may be employed for *in vitro* selection of successfully transduced stem cells prior to transplantation into humans. The human MGMT transgene will be employed because its expression in stem cells is sufficient to protect them from the toxic effects of specific alkylating agents (e.g. BCNU; [Maze *et al.*, 1996]), allowing rapid *in vitro* selection of gene-modified stem cells. We believe that inclusion of MGMT as a selectable marker gene may eventually enable *in vitro* or *in vivo* enrichment of stem cells co-transduced with a therapeutic gene (e.g. glucocerebrosidase). rsGFP and human MGMT will be employed

from the rsGFP-MGMT family of constructs (Fig. 6; all of these constructs have already been generated). The phosphoglycerate kinase (pgk) promoter, highly active in immature and mature hematopoietic cells, as well as in fibroblasts, will be used to drive expression of both rsGFP and MGMT genes.

5 There are two potential strategies for stable in vitro transduction of quiescent hematopoietic stem cells. The first is to facilitate the integration event directly in the quiescent cell ex vivo (denoted 'integration-quiescent'). The second is to deliver the DNA (perhaps together with integration enzymes) to the quiescent cell and establish a stable transduction intermediate, which can later be integrated when the cell is returned to its in vivo environment and undergoes a self-renewing cell division (denoted 'integration-quiescent/cycling'). There is evidence (AAV vectors [Russell *et al.*, 1994] and HIV-1 based vectors [Naldini *et al.*, 1996]), for the existence of such transduction intermediates in quiescent cells, capable of subsequent integration when cells go into cycle.

15 A plasmid backbone containing the AAV ITRs has been completed, and the rsGFP-MGMT sequences inserted between the Pac I and Asc I sites to generate prsGFP-MGMT/ITR. Linearized ITR-flanked rsGFP-MGMT sequences will be obtained by digestion with Fse I and Sfi I. Circularized rsGFP-MGMT/ITR sequences, absent the plasmid backbone, will be generated as diagramed in Figure 9. The Sfi I site has been converted in prsGFP-MGMT/ITR to create a second Fse I site. The construct will be linearized and backbone plasmid sequences removed via Fse I digestion, religated to circularize at the Fse I site, and circular molecules purified on an agarose gel prior to microinjection.

20 Co-delivery of Integrase with LTR-flanked transgenes and co-delivery of Rep⁷⁸ with ITR-flanked transgenes are expected to increase the rate of integration. Examining both linear and circular ITR-containing constructs will demonstrate which substrate Rep⁷⁸ utilizes for wild-type AAV integration.

25 The joint delivery of naked DNA (i.e., DNA not within a delivery vehicle such as liposome) and Integrase or Rep⁷⁸ to cell nuclei has not previously been attempted, and as part of the present invention provides an improved approach to genetically modifying important cell types.

30

EXAMPLE 10
LTR/INTEGRASE AND ITR/Rep⁷⁸-MEDIATED INTEGRATION

5 A characteristic of retroviruses (both lentiviruses (e.g. HIV-1) and type C retroviruses (e.g. M-MuLV)) and wild-type AAV is the ability to incorporate gene sequences, with high efficiency, into the chromosomal DNA of the target cell. Provided that the multiplicity of infection is sufficiently high, a significant fraction, if not all, of the target cells may acquire an integrated proviral copy. The only retroviral LTR sequences required for in vitro
10 integration reactions are the extreme 10-12 bp LTR termini [Goff, 1992; Goodarzi *et al.*, 1995; Reicin *et al.*, 1995; LaFemina *et al.*, 1991]. The retroviral Integrase enzyme interacts with these sequences to facilitate integration in vitro and in vivo [Goff, 1992; Goodarzi *et al.*, 1995; Reicin *et al.*, 1995; LaFemina *et al.*, 1991]. There appears to be no site specificity for integration of retroviral vectors, although there is a preference for integration into the
15 chromatin of transcriptionally active genes [Vijaya *et al.*, 1986; Withers-Ward *et al.*, 1994] and a preference with respect to nucleosomal conformation [Pruss *et al.*, 1994]. Wild-type AAV is unique in its preferential integration into a specific region of the human genome. AAV Rep⁷⁸ is required for chromosome 19 specific integration, since rep⁻ AAV vectors do not have the same pattern of site-specific integration as rep⁺ AAV vectors [Muzyczka, 1992].
20 The Rep⁷⁸ protein is believed to play several essential roles in chromosome 19 specific AAV integration -- mediating the formation of a complex between a 12 nucleotide sequence within the ITRs and a similar sequence on chromosome 19 (the AAVS1 region) prior to integration, and also introducing a strand-specific break within AAVS1 [Linden *et al.*, 1996]. It was recently reported that co-transfection of cells with an ITR-flanked gene (lacZ) together with
25 a Rep⁷⁸ expression construct yielded a 10 fold increase in the number of stable lacZ-expressing cells. In addition, the majority of integrants were Chromosome 19 specific and constructs up to 35 kb in size could be integrated - provided they contained at least a single ITR [Natsoulis *et al.*, 1995]. These results strongly indicate that simple delivery of ITR-flanked sequences together with Rep⁷⁸ protein will also facilitate integration - likely to occur
30 in a site-specific, or at least site-preferred, manner. Providing the purified Integrase or Rep⁷⁸ protein together with the delivered DNA, possibly as a preformed DNA/protein complex, may have advantages over producing the integration proteins in cells from an expression construct. Already delivering an Δ LTR/Integrase or ITR/Rep⁷⁸ DNA/protein complex will

eliminate the need for the expressed proteins to translocate from the cytoplasm to the nucleus, and then to find and form complexes with the Δ LTR or ITR sequences.

HIV-1 is capable of delivering proviral DNA to nuclei of quiescent cells and stably transducing quiescent macrophages [Wenberg *et al.*, 1991; Lewis *et al.*, 1992]. Although it has not yet been conclusively demonstrated that HIV-1 based vectors can integrate in G₀ cells, they are capable of establishing a stable transduction intermediate in quiescent Rat 208F fibroblasts ('integration-quiescent/cycling') [Naldini *et al.*, 1996]. Cells recruited from quiescence even 8 days after original infection had stable transduction frequencies equal to 50% of those infected while in a cycling state. We have chosen to initially examine HIV-1 Integrase (rather than M-MuLV Integrase) will be examined for its ability to facilitate integration. HIV-1 is known to be capable of the 'full-site' integration events in vitro [Goodarzi *et al.*, 1995] and to stably transduce quiescent cells. Whether M-MuLV Integrase is also capable of accomplishing integration in quiescent cells is unknown, since pre-integration complexes of wild-type M-MuLV and M-MuLV vectors are incapable of transport into the nuclei of quiescent cells [Miller *et al.*, 1990]. However, previous studies have indicated that the actual integration of M-MuLV sequences need not occur during mitosis [Roe *et al.*, 1993].

High frequencies of integration are also observed for cells transduced with rep⁺ AAV vectors [Muzyczka, 1992]. Although the precise structure of the AAV vector DNA prior to integration is unknown, it is likely that it either exists as a linear duplex flanked by ITRs or, as is postulated to be the case for wild-type AAV, is circularized in the nucleus prior to integration [Linden *et al.*, 1996]. AAV vector DNA integrates into cellular DNA as one to several tandem copies joined to chromosomal DNA through the ITR termini [Flotte and Carter, 1995]. When linked to other transgene sequences, the ITRs alone are sufficient to confer increased rates of integration [Philip *et al.*, 1994]. There is controversy regarding the ability of rep⁺ AAV vectors to directly transduce non-cycling cells [Podsakoff *et al.*, 1994; Russell *et al.*, 1994]. Although AAV-vectors prefer cycling cells for transduction, they either directly integrate at low frequency in non-cycling cells ('integration-quiescent') [Podsakoff *et al.*, 1994] or exist as single stranded episomes in non-cycling cells and subsequently integrate as double stranded DNA when the cells go through S-phase ('integration-quiescent/cycling') [Russell *et al.*, 1994].

25

30 The present example demonstrates the utility of the present invention for increased frequency of stable transduction with co-delivery of Integrase_{HIV-1} together with transgene constructs flanked by Δ LTR_{HIV-1} sequences. The ability of Integrase_{HIV-1} to facilitate integration of linearized Δ LTR_{HIV-1}-flanked pgk-tk sequences is also further identified. The pgk-tk sequences were flanked by the most terminal 20 bp HIV-1 LTR U3/U5 sequences to generate pgk-tk/ Δ LTR_{HIV-1} (Figure 7). This linear construct was generated by PCR

employing primers 35-36 bases in length, with 15-16 bases corresponding to the extreme pgk-tk sequences and 20 bases identical to LTR_{HIV-1} U3/U5 termini. Rat-2tk(-) cells were microinjected with either PCR-generated linear molecules of pgk-tk/ Δ LTR_{HIV-1} pre-incubated with Integrase_{HIV-1}, or with PCR-generated linear molecules of pgk-tk/ Δ LTR_{HIV-1} alone.

5 Since 20-30 kb sequences can be generated by PCR amplification using optimized protocols, this approach should be generally applicable to larger transgene constructs. The HIV-1_{NL4-3} Integrase enzyme was utilized. This integrase enzyme has been modified at two amino acids to make it more soluble, without affecting its in vitro integration ability. This general technique is known to those of skill in the art, and is described in Jenkins *et al.*, 1996. The

10 expression construct pINS.D.His.Sol may be used to express and purify additional enzyme, as needed.

Rat-2(tk-) cells were grown in Dulbecco's Modified Eagles Medium (DMEM) containing 10% Fetal Bovine Serum (FBS), 100 units/ml penicillin, 100 microgram/ml streptomycin, and 2 mM glutamine. On the day prior to injection, cells were plated at 20,000

15 cells per 35 mm dishes that previously had 0.4 mm rectangular grids etched into the tissue culture surface. DNA or DNA + protein were delivered into the nuclei of cells using borosilicate microinjection needles having a tip outer diameter of approximately 0.3 - 0.45 micron. Solutions of DNA alone contained approximately 42 ng/microliter of pgk-tk/ Δ LTR_{HIV-1} (23 nM) in 1x microinjection buffer (50 mM Hepes [pH 7.2], 100 mM KCl, 5

20 mM NaH₂PO₄) containing 10 mM MgCl₂. Injection of 5-10 femtoliters is estimated to deliver approximately 70-140 DNA molecules per cell. Solutions of DNA and protein contained the same concentration of DNA together with 17 ng/microliter Integrase_{HIV-1} (445 nM). This value was chosen to yield approximately 20 molecules of injected protein per molecule of injected DNA. The DNA solution was passed through a 0.1 micron filter to

25 remove any aggregates including crystals believed to be MgPO₄.

Typically, 25-30 cells were injected per 35 mm dish, with only one cell injected per square of the gridded plate. This was done to facilitate scoring of stably transduced colonies after selection in media containing HAT (0.1 mM sodium hypoxanthine, 0.4 micro M aminopterin, 16 micro M thymidine). The day following injection, the media was removed

30 and media containing HAT was added. HAT medium was changed every 3-5 days. 5-7 days post injection, dishes were scanned under the microscope, and the position of potential colonies growing out of stably transduced cells was marked on the bottom surface of

dish. Colonies consisted of 50-200 cells which continued to show proliferation of cells. The colonies were checked by scanning the dishes twice per week for 3 weeks. Only stable colonies (i.e., present at 3 weeks postinjection) were analyzed in the present studies.

- The present studies were performed with pgk-tk/ Δ LTR_{HIV-1}, with or without
- 5 Integrase_{HIV-1}. The results are presented in Table 1. These data demonstrate that the frequency of stable transductants for pgk-tk/ Δ LTR_{HIV-1} co-delivered with Integrase_{HIV-1} was 4.5% vs. 1.9% for pgk-tk/ Δ LTR_{HIV-1} alone. This 2.4 fold increase in stable transduction frequency was shown to be significant ($p < .05$) in a paired Student t test (2 tailed). Even further optimization may be appreciated by varying, for example, 1) the relative ratio of
- 10 Integrase molecules to DNA molecules, 2) the composition of the microinjection buffer, 3) the conditions (e.g. temperature) for pre-incubating the DNA together with Integrase prior to microinjection. Even greater increases in stable transduction efficiency may thus be achieved employing the techniques of the present invention.

Table 1
HIV-1 Δ LTR/HIV-1 Integrase Strategy

	<u>Pgk-tk/ΔLTR HIV-1</u>	<u>Pgk-tk/ΔLTR HIV-1 + Integrase HIV-1</u>
5	2/56 (3.6%)	1/47 (2.1%)
	3/59 (5.1%)	5/62 (8.1%)
	1/50 (2%)	3/50 (6%)
	0/50 (0%)	2/50 (4%)
	0/50 (0%)	2/50 (4%)
10	0/50 (0%)	1/50 (2%)
	<hr/> 6/315 (1.9%)	<hr/> 14/309 (4.5%) 2.4-fold improvement

Statistical analysis of the data in Table 1 demonstrates a statistically significant improvement in the number of cells in which stable DNA integration was obtained. This analysis revealed a statistically significant improvement (paired Student t test (2-tailed), $p < .05$)

EXAMPLE 12
STABLE TRANSDUCTION WITH CO-DELIVERY
OF REP⁷⁸ AND AAV ITR FLANKED TRANSGENE CONSTRUCTS

5 The present example is provided to demonstrate the use of the present invention for use in conjunction with proteins. By way of example, the protein used in the present study was an enzyme, Rep⁷⁸. Those of ordinary skill in the art will appreciate that many other proteins may be used given the present disclosure.

10 The present example demonstrates the utility of the present invention for providing increased frequency of stable transduction with co-delivery of Rep⁷⁸ together with transgene constructs flanked by AAV ITR sequences. For evaluation of the ITR/Rep⁷⁸ strategy, cells were microinjected either with linearized pgk-tk/ITR co-delivered with Rep⁷⁸, or linearized pgk-tk/ITR alone. Linearized ITR-flanked pgk-tk sequences were obtained by digestion with Fse I and Sfi I, and then gel purified to eliminate bacterial plasmid sequences. The purified
15 MBP-Rep⁷⁸ protein described in Figure 4 was used. MBP-Rep⁷⁸ has been previously observed by the inventors to be active in *in vitro* ITR binding and endonuclease reactions. These studies were performed as described in Example 11 except that the DNA solution contained pgk-tk/ITR at a concentration of 50 ng/microliter (23 nM), the DNA/protein solution contained pgk-tk/ITR at 50 ng/microliter and MBP-Rep⁷⁸ at 56 ng/microliter
20 (475 nM), and the MgCl₂ concentration was 2 mM. These values were chosen to yield approximately 20 molecules of injected protein per molecule of injected DNA. Although the exact volume delivered per cell was not known, injection of 5-10 femtoliters would deliver approximately 70-140 DNA molecules per cell.

25 The present results are provided in Table 2. A 2.3-fold increase in stable transduction frequency was achieved when Rep⁷⁸ was included together with pgk-tk/ITR. For these studies, the MBP-Rep⁷⁸ protein was added to the DNA solution immediately prior to loading of solution into the microinjection needle. Comparison with an initial experiment (not shown) in which the DNA/protein solution was not prepared immediately prior to microinjection, but rather was maintained for several hours before microinjection, suggests
30 that the timing of addition of protein to DNA may be important.

Table 2
AAV ITR/Rep⁷⁸ Strategy

	<u>pgk-tk/ITR</u>	<u>pgk-tk/ITR + Rep⁷⁸</u>
5	3/72 (4.2%)	5/80 (6.3%)
	4/76 (5.3%)	8/66 (12.1%)
	2/76 (2.6%)	7/72 (8.7%)
	<hr/>	<hr/>
	9/224 (4.0%)	20/218 (9.2%)
10		2.3-fold improvement

EXAMPLE 13
CIRCULARIZED CONSTRUCTS FOR
15 NUCLEIC ACID INTEGRATION

The present example demonstrates the utility of the present invention for the generation of covalently closed circles for facilitating integration. Since circular double-stranded proviral DNA may be the relevant substrate for normal AAV integration, and
20 possibly for retroviral integration, it may be useful to first circularize the transgene constructs. One such circularized construct is shown for cir-rsGFP-MGMT/ITR in Figure 9. A plasmid backbone containing the AAV ITRs has been constructed, and the rsGFP-MGMT sequences inserted between the Pac I and Asc I sites to generate prsGFP-MGMT/ITR. Linearized ITR-flanked rsGFP-MGMT sequences have been obtained as described above by
25 digestion with Fse I and Sfi I. The Sfi I site (the backbone plasmid sequences) in prs GFP-MGMT/ITR was converted to create a second Fse I site. The molecule will be linearized and removed via Fse I digestion. The molecule will then be religated to circularize at the Fse I site. The circular molecules will then be purified on an agarose gel prior to microinjection.

The above strategy may also be used to facilitate retroviral Integrase-mediated
30 integration of transgene constructs. Although the constructs shown in Figure 6 containing ΔLTR sequences (or possibly also the complete LTR sequences) are all linear, it is possible that presenting the transgene flanked by ΔLTR or LTR sequences on a circular construct

would lead to increased frequencies of integration. For example, although the substrate for retroviral provirus integration is believed to be a linear molecule flanked by LTRs, it is conceivable that the circular proviral molecules (containing either one or two LTRs) present in the nucleus of retrovirally infected cells are also potential substrates for integration. In fact, use of such circular constructs, co-delivered with retroviral Integrase protein may lead to increased efficiency of integration in comparison with the linear form. It is possible that the LTRs, or LTR terminal sequences included in such circular constructs may be either in juxtaposition to each other, or separated by some distance. By way of example, this distance may be defined by a number of nucleic acid bases. For example, the number of nucleic acid bases separating the first and the second LTR terminal sequences could be between 2 to about 200 nucleotide bases. In some embodiments of the circularized nucleic acid the LTR terminal fragments are separated by about 10 to about 20 nucleotide bases.

EXAMPLE 14 SITE-SPECIFIC TARGETING OF TRANSGENE INTEGRATION BY
EMPLOYING RETROVIRAL INTEGRASE PROTEIN FUSED TO PROTEINS
HAVING HIGH SPECIFICITY OF BINDING TO SPECIFIC DNA SEQUENCES.

Wild-type AAV exhibits preferential integration into a specific region of the human genome. AAV Rep⁷⁸ is required for chromosome 19 specific integration, since rep⁻ AAV vectors do not have the same pattern of site-specific integration as rep⁺ AAV vectors [Muzyczka, 1992]. The Rep⁷⁸ protein is believed to play several essential roles in chromosome 19 specific AAV integration -- mediating the formation of a complex between a 12 nucleotide sequence within the ITRs and a similar sequence on chromosome 19 (the AAVS1 region) prior to integration, and also introducing a strand-specific break within AAVS1 [Linden *et al.*, 1996]. As such, Rep⁷⁸ may itself be described as a protein having both a binding activity for specific DNA sequences, and an integrase activity.

There appears to be no site specificity for integration of retroviral vectors, although there is a preference for integration into the chromatin of transcriptionally active genes [Vijaya *et al.*, 1986; Withers-Ward *et al.*, 1994] and a preference with respect to nucleosomal conformation [Pruss *et al.*, 1994]. However, it may ultimately be possible to target the precise integration site by employing Integrase linked to high-specificity DNA binding domains (Fig. 2) [Goulaouic and Chow, 1996; Bushman, 1994]. The DNA binding domain

could either be derived from an existing DNA binding protein, or a novel protein could be designed and synthesized to have a high affinity binding specificity for specific genomic DNA sequences. For example, it is possible that specific targeting of transgenes to the globin locus (by fusing retroviral integrase to the DNA binding domains of GATA-1 or NF-E2 erythroid specific transcription factors) would facilitate transgene expression specifically in erythroid cells. Another potential example would be targeting the integration to chromatin known to be 'open' in monocyte/macrophages may facilitate long-term expression of therapeutic genes for lysosomal storage diseases. It may be possible to increase the affinity and specificity of DNA binding proteins for specific DNA sequences by structural analysis (e.g. X-ray crystallographic and/or NMR analysis of the interaction between the DNA binding domain and the DNA target) of the protein and site directed mutagenesis. For example, mutants of the DNA binding domain of the c-myc protein having increased affinity for DNA have been described.

15

EXAMPLE 15 USE OF CONSTRUCTS EXPRESSING INTEGRATION ENZYMES

In some embodiments, this invention provides for the co-delivery to a cell of a first and a second DNA sequence. This first and second nucleic acid sequence may be created as two separate constructs, one containing the transgene(s) of interest flanked by appropriate LTR or ITR sequences, and the other being an expression construct encoding a protein, particularly an enzyme capable of facilitating the incorporation of the transgene sequence into the cellular chromosomal DNA (i.e. retroviral integrase or Rep⁷⁸). Microinjection would be capable of co-delivering both the transgene construct and integrase-expression construct to the nucleus of cells to be genetically modified. After expression and then translation of the integrase protein in the cytoplasm, it would necessarily have to translocate to the nucleus to interact with the transgene construct to facilitate integration. It has previously been described that certain retroviral integrases localize to the nucleus after expression in cells. An expression construct for the M-MuLV Integrase under the control of the cytomegalovirus (CMV) promoter/enhancer sequences has been prepared by the present inventors. In addition, an expression construct for the AAV Rep⁷⁸ protein under the control of the CMV promoter/enhancer sequences has also been generated.

30

REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by
 5 reference.

- Abkowitz JL, Catlin SN, Gutter P, "Evidence that hematopoiesis may be a stochastic process *in vivo*," *Nature Medicine*, 2:190, 1996.
- 10 Akkina, RK, Rosenblatt, JD, Campbell, AG, Chen, IS, Zack, JA, "Modeling human lymphoid precursor cell gene therapy in the SCID-hu mouse," *Blood*, 84:1393, 1994.
- Batchu, RB, Miles, DA, Rechtin, TM, Drake, RR, Hermonat, PL, "Cloning, Expression and Purification of Full Length Rep⁷⁸ of Adeno-Associated Virus as a Fusion Protein with
 15 Maltose Binding Protein in *Escherichia coli*," *BBRC*, 208:714-720, 1995.
- Brenner, MK, Rill, DR, Holladay, MS, Heslop, HE, Moen, RC, Buschle, M, Krance, RA, Santana, VM, Anderson, WF, Ihle, JN, "Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients," *Lancet*, 342:1134,
 20 1993.
- Brinster, RL, Allen, JM, Behringer, RR, Gelinas, RE, Palmiter, RD, 'Introns increase transcriptional efficiency in transgenic mice," *Proc. Natl. Acad. Sci. USA*, 85:836, 1988.
- 25 Bushman, FD, "Tethering human immunodeficiency virus 1 integrase to a DNA site directs integration to nearby sequences," *Proc. Natl. Acad. Sci. USA*, 91:9233, 1994.
- Cassel, A, Cortler-Fox, M, Doren, S, Dunbar, C, "Retroviral-mediated gene transfer into CD34-enriched human peripheral blood stem cells," *Exp. Hematol.*, 21:585, 1995.
 30
- Caterina, JJ, Ciavatta, DJ, Donze, D, Behringer, RR, Townes, TM, "Multiple elements in human beta-globin locus control region 5' HS 2 are involved in enhancer activity ad position-independent, transgene expression," *Nucleic Acids Res.*, 22:1006, 1994.
- 35 Challita, PM, Kohn, DB, "Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation *in vivo*," *Proc. Natl. Acad. Sci. USA*, 91:2567, 1994.
- Chaudhary, PM, Roninson, IB, "Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells," *Cell*, 66:85, 1991.
 40
- Crooks, GM, Kohn, DB, "Growth factors increase amphotropic retrovirus binding to human CD34+ bone marrow progenitor cells," *Blood*, 3290, 1995.
- 45 Dick, JE, Larochelle, A, Vormoor, J, Hanenburg, H, Williams, DA, "Evaluation of Procedures for Gene Transfer into Primitive Human Hematopoietic Cells Using the

- SCID-Repopulation Assay," *Gene Therapy for Hematopoietic Stem Cells in Genetic Disease and Cancer*, 1996.
- 5 Dick JE, "Normal and leukemic human stem cells assayed in SCID mice," *Seminars in Immunology*, 8:197, 1996.
- Dotan, I, Scottoline, BP, Heuer, TS, Brown, PO, "Characterization of recombinant murine leukemia virus integrase," *J. Virol.*, 69:456, 1995.
- 10 Einerhand, MP, Antoniou, M, Zolotukhin, S, Muzyczka, N, Berns, KI, Grosveld, F, Valerio, D, "Regulated high-level human beta-globin gene expression in erythroid cells following recombinant adeno-associated virus-mediated gene transfer," *Gene Ther.*, 2:336, 1995.
- 15 Emerson SG, "Ex vivo expansion of hematopoietic precursors, progenitors, and stem cells: the next generation of cellular therapeutics," *Blood*, 87:3082, 1996.
- Farnet, CM, Bushman, FD, "HIV-1 cDNA Integration: Requirement of HMG I(Y) Protein for Function of Preintegration Complexes *In Vitro*," *Cell*, 88:483-492, February, 1997.
- 20 Flotte, TR, Carter, BJ, "Adeno-associated virus vectors for gene therapy," *Gene Ther.*, 2:357, 1995.
- Gnirke, A, Huxley, C, "Transfer of the human HPRT and GART genes from yeast to mammalian cells by microinjection of YAC DNA," *Somat. Cell. Mol. Genet.*, 17:573, 1991.
- 25 Goff, SP, "Genetics of Retroviral Integration," *Annu. Rev. Genet.*, 26:527, 1992.
- Goodarzi, G, IM, GJ, Brackmann, K, Grandgenett, D, "Concerted Integration of etrovirus-Like DNA by human Immunodeficiency Vius Type 1 Integrase," *Journal of Virology*, 69:6090, 1995.
- 30 Goulaouic, H, Chow, SA, "Directed integration of viral DNA mediated by fusion proteins consisting of human immunodeficiency virus type 1 integrase and *Escherichia coli* LexA protein," *J. Virol.*, 70:37, 1996.
- 35 Halbert, CL, Alexander, IE, Wolgamot, GM, Miller, AD, "Adeno-associated virus vectors transduce primary cells much less efficiently than immortalized cells," *J. Virol.*, 69:1473, 1995.
- 40 Harrington, JJ, Bokkelen, GV, Mays, RW, Gustashaw, K, Willard, HF, "Formation of de novo centromeres and construction of first-generation human artificial microchromosomes," *Nature Genetics*, 15:345, 1997.
- 45 Harrison, GS, Wang, Y, Tomczak, J, Hogan, C, Shpall, EJ, Curiel, TJ, Felgner, PL, "Optimization of Gene Transfer Using Cationic Lipids in Cell Lines and Primary Human CD4⁺ and CD34⁺ Hematopoietic Cells," *BioTechniques*, 19:816, 1995.
- Hughes, PF, Eaves, CJ, Hoge, DE, Humphries, RK, "High-efficiency gene transfer to human hematopoietic cells maintained in long-term marrow culture," *Blood*, 74:1915, 1989.

- Jandl JH, *BLOOD: Textbook of Hematology*, 136, 1987
- 5 Johnson *et al.*, "Characterization of the Forward and Reverse Integration Reactions of the Moloney Murine Leukemia Virus Integrase Protein Purified from *Escherichia coli*," *JBC*, 268:1462-9, 1993.
- 10 Jones RJ, Collector MI, Barber JP, Vala MS, Fackler MJ, May S, Gritti CA, Hawkins AL, Zehobauer BA, Hilton J, Colvin OM, Sharkis SJ, "Characterization of Mouse Lymphohematopoietic stem cells lacking spleen colony-forming activity," *Blood*, 88:487, 1996.
- Jones, RJ, Wagner, JE, Celano, P, Zicha, MS, Sharkis, SJ, "Separation of pluripotent hematopoietic stem cells from spleen colony forming cells," *Nature*, 347:188, 1995.
- 15 Kalpana, GV, Marmon, S, Wang, W, Crabtree, GR, Goff, SP, "Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5," *Science*, 266:2002, 1994.
- 20 Kohn, DB, Weinberg KL, Nolte, JA, Heiss, LN, Lenarsky, C, Crooks, GM, Hanley, ME, Annett, G, Brooks, JS, el-Khoureiy, A, *et al.*, "Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency," *Nature Medicine*, 1:1017, 1995.
- 25 Kollias, G, Grosveld, F, "The study of gene regulation in transgenic mice," in *Transgenic Animals*, Grosveld, F and Kollias, G (eds.), San Diego, California, Academic Press Limited, p. 79, 1992.
- 30 Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, Ciocci G, Carrier C, Stevens CE, Rubinstein P, "Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients," *New England Journal of Medicine*, 335:157, 1996.
- LaFemina, RL, Callahan, PL, Cordingley, MG, "Substrate Specificity of Recombinant Human Immunodeficiency Virus Integrase Protein," *Journal of Virology*, 65:5624, 1991.
- 35 Lewis, P, Hensel, M, Emerman, M, "Human immunodeficiency virus infection of cells arrested in the cell cycle," *EMBO Journal*, 11:3053, 1992.
- Linden, RM, Winocour, E, Berns, KI, "The recombination signals for adeno-associated virus site specific integration," *Proc. Natl. Acad. Sci. USA*, 93:7966, 1996.
- 40 Lu, M, Mauyama, M, Zhang, N, Levine, F, Friedmann, T, Ho, AD, "High efficiency retroviral-mediated gene transduction into CD34+ cells purified from peripheral blood of breast cancer patients primed with chemotherapy and granulocyte-macrophage colony-stimulating factor," *Hum. Gene Ther.*, 5:203, 1994.
- 45 Mayani, H, Dragowska, W, Lansdorp, PM, "Characterization of Functionally Distinct Subpopulations of CD34+ Cord Blood Cells in Serum-Free Long-Term Cultures Supplemented with Hematopoietic Cytokines," *Blood*, 82:2664, 1993.

- Maze, R, Carney, JP, Kelley, MR, Glassner, BJ, Williams, DA, Samson, L, "Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1.3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent," *Proc. Natl. Acad. Sci. USA*, 93:206, 1996.
- 5 Miller, DG, Adam, MA, Miller, AD; "Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection," *Mol. Cell Biol.*, 10:4239, 1990.
- 10 Miller, JL, Donahue, RE, Sellers, SE, Samulski, RJ, Young, NS, Nienhuis, AW, "Recombinant adeno-associated virus (rAAV)-mediated expression of a human gamma-globin gene in human progenitor-derived erythroid cells," *Proc. Natl. Acad. Sci. USA*, 91:10183, 1994.
- 15 Muzyczka, N, "Use of adeno-associated virus as a general transduction vector for mammalian cells," *Curr. Top. Microbiol. Immunol.*, 158:97, 1992.
- 20 Naldini, L, Blomer, U, Gallay, P, Ory, D, Mulligan, R, Gage, FH, Verma, IM, Trono, D, "In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector," *Science*, 272:263, 1996.
- Natsoulis, G, Surosky, R, Godwin, S, McQuiston, S, Kurtzman, G, "A system for specifically targeting genes to Chromosome 19," *Blood*, 86:236a, 1995.
- 25 Nolte, JA, Dao, M, Wells, S, Smogorzewska, EM, Kohn, DB, "Transduction of pluripotent human hematopoietic stem cells demonstrated by clonal analysis after engraftment in immune deficient mice," *Proc. Natl. Acad. Sci. USA*, 93:2414, 1996.
- Ogawa, M., "Differentiation and Proliferation of Hematopoietic Stem Cells," *Blood*, 81:2844, 1993.
- 30 Orkin, SH, Motulsky, AG, "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy," 1996.
- 35 Osawa M, Hanada K, Hamada H, Nakauchi H, "Long-term Lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell," *Science*, 273:242, 1996.
- 40 Pepperkok, R, Schneider, C, Philipson, L, Ansorge, W, "Single cell assay with an automated capillary microinjection system," *Exp. Cell. Res.*, 178:369, 1988.
- 45 Philip, R, Brunette, E, Kilinski, L, Muruges, D, McNally, MA, Ucar, K, Rosenblatt, J, Okarma, TB, Lebkowski, JS, "Efficient and sustained gene expression in primary T lymphocytes and primary cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes," *Mol. Cell. Biol.*, 14:2411, 1994.
- Podsakoff, G, Wong, KK, Jr., Chatterjee, S, "Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors," *J. Virol.*, 68:5656, 1994.

- Pruss, D, Reeves, R, Bushman, FD, Wolffe, AP, "The influence of DNA and nucleosome structure on integration events directed by HIV integrase," *J. Biol. Chem.*, 269:25031, 1994.
- 5 Pryciak. PM, Sil, A, Varmus, HE, "Retroviral integration into minichromosomes *in vitro*," *EMBO Journal*, 11:291, 1992.
- 10 Reicin, AS, Kalpana, G, Paik, S, Marmon, S, Goff, S, "Sequences in the Human Immunodeficiency Virus Type 1 U3 Region Required for *in vivo* and *in vitro* Integration," *Journal of Virology*, 69:5904, 1995.
- 15 Russell, DW, Miller, AD, Alexander, IE, "Adeno-associated virus vectors preferentially transduce cells in S phase," *Proc. Natl. Acad. Sci. USA*, 91:8915, 1994.
- 20 Sadelain, M, Wang, CH, Antoniou, M, Grosveld, F, Mulligan, RC, "Generation of a high-titer retroviral vector capable of expressing high levels of the human beta-globin gene," *Proc. Natl. Acad. Sci. USA*, 92:6728, 1995.
- 25 Serrano F, Chinen J, Aguilar-Cardova E, Belmont JW, "Anti HIV-1 gene therapy with *Trev*. high level of hematopoietic engraftment and retroviral transduction in the CD34⁺ hu/scid mouse," *Gene Therapy for Hematopoietic Stem Cells in Genetic Disease and Cancer*, 22, 1996.
- 30 Spangrude GJ, Heimfeld S, Weissman IL, "Purification and Characterization of Mouse Hematopoietic Stem Cells," *Science*, 241:58, 1988.
- 35 Talbot, D, Philipsen, S, Fraser, P, Grosveld, F, "Detailed analysis of the site 3 region of the human beta-globin dominant control region," *EMBO Journal*, 9:2169, 1990.
- 40 Toneguzzo, F, Keating, A, "Stable expression of selectable genes introduced into human hematopoietic stem cells by electric field-mediated DNA transfer," *Proc. Natl. Acad. Sci. USA*, 83:3496, 1986.
- 45 Vijaya, S, Steffen, DL, Robinson, HL, "Acceptor sites for retroviral integrations map near DNase I-hypersensitive sites in chromatin," *Journal of Virology*, 60:683, 1986.
- Wenberg, JB, Matthews, TJ, Cullen, BR, Malim, MH, "Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes," *Journal of Experimental Medicine*, 174:1477, 1991.
- Withers-Ward, ES, Kitamura, Y, Barnes, JP, Coffin, JM, "Distribution of targets for avian retrovirus DNA integration *in vivo*," *Genes & Development*, 8:1473, 1994.
- Woffendin C, Yang ZY, Udaykomar, Xu L, Yang NS, Sheehy MJ, Nabel GJ, "Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells," *Proc. Natl. Acad. Sci. USA*, 91:11581, 1994

Zack, JA, Arrigo, SJ, Weitsman, SR, Go, AS, Haislip, A, Chen, IS, "HIV-1 Entry into Quiescent primary Lymphocytes: Molecular Analysis Reveals a Labile, Latent Viral Structure," *Cell*, 61:213, 1990.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5 (i) APPLICANT: Gene-Cell, Inc.

(ii) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Gene-Cell, Inc.
(B) STREET: 1010 Hercules Avenue
10 (C) CITY: Houston
(D) STATE: Texas
(E) COUNTRY: USA
(F) ZIP: 77058
(G) TELEPHONE NUMBER: (512) 495-8400

15

(iii) TITLE OF INVENTION: NUCLEIC ACID CONSTRUCTS AND
USES THEREOF FOR DIRECT NUCLEIC
ACID INCORPORATION INTO CELLS

20 (iv) NUMBER OF SEQUENCES: 2

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
25 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(2) INFORMATION FOR SEQ ID NO:1:

30

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
35 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ACTGGAAGGG CTAATTCAC TGTGGGAAGG GCGATC

36

5

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 35 base pairs

10

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

15

ACTGCTAGAG ATTTCCACA CAGGAAACAG CTATG

35

WHAT IS CLAIMED IS:

1. A method for increasing incorporation of a naked nucleic acid sequence of a gene of interest into a chromosomal nucleic acid of a cell comprising:
 - 5 preparing a composition comprising a protein and a transgene construct, said transgene construct having a nucleic acid sequence of interest flanked by a long terminal repeat sequence or a fragment thereof, and
 - introducing the composition to a nucleus of the cell.wherein stable incorporation of the nucleic acid of interest into the chromosomal nucleic acid
10 of the cell is enhanced in the presence of the protein over incorporation of the nucleic acid of interest in the absence of the protein.
2. The method of claim 1 wherein the protein is further defined as an integrase enzyme.
- 15 3. The method of claim 1 wherein the long terminal repeat sequence is further defined as a retroviral long terminal repeat or a fragment thereof.
4. The method of claim 1 wherein the enzyme is further defined as a retroviral integrase.
- 20 5. The method of claim 1 wherein the protein is further defined as a fusion protein comprising an enzyme fused to a nucleic acid binding protein.
6. The method of claim 5 wherein the protein is further defined as comprising an enzyme fused to a DNA binding domain of GATA 1 or NFE 2 capable of binding a sequence
25 within a globin locus.
7. The method of claim 6 wherein the enzyme is a retroviral integrase enzyme.
8. The method of claim 4 or 6 wherein the retroviral integrase enzyme is further defined
30 as a recombinant retroviral integrase protein.
9. The method of claim 8 wherein the recombinant retroviral integrase protein is HIV-1, M-MuLV, SIV, FeLV OR EIAV.

10. The method of claim 1 wherein the cell is a mammalian cell.
11. The method of claim 10 wherein the mammalian cell is a fibroblast, hematopoietic stem cell, endothelial, mesenchymal, epithelial, or glial cell.
- 5 12. The method of claim 1 wherein the transgene construct is defined as rsGFP-MGMT/LTR.
- 10 13. The method of claim 6 wherein the nucleic acid binding protein is further defined as capable of binding a nucleic acid sequence.
14. The method of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 wherein the composition is introduced into the nucleus of a cell by microinjection.
- 15 15. The method of claim 1 wherein the transgene construct is MGMT/MDR-1.
16. A method for increasing incorporation of a nucleic acid sequence of interest into chromosomal nucleic acid of a cell comprising:
preparing a composition comprising an integration enzyme and a transgene construct
20. having a nucleic acid sequence flanked by an adeno-associated virus inverted terminal repeat or fragment thereof; and
introducing the composition to the cell.
17. The method of claim 16 wherein the integration enzyme is Rep⁷⁸.
- 25 18. The method of claim 16 wherein the transgene construct is prsGFP-MGMT/ITR.
19. The method of claim 16 wherein the composition is introduced into the cell through microinjection.
- 30 20. The method of claim 16 wherein the cell is a mammalian cell.
21. A composition comprising:

a transgene construct having a nucleic acid sequence flanked by long terminal repeat or a fragment thereof; and
an enzyme capable of facilitating the integration of the nucleic acid sequence into nucleic acid of a cell.

5

22. The composition of claim 21 wherein the long terminal repeat sequence comprises a length of about 10 to about 20 base pairs in length.

10

23. The composition of claim 21 wherein the transgene construct is rsGFP-MGMT/LTR.

24. A composition comprising:

a transgene construct having a nucleic acid sequence of interest flanked by an adeno-associated virus inverted terminal repeat sequence or fragment thereof;
and

15

an integrase protein.

25. The composition of claim 24 wherein the integrase protein is Rep⁷⁸.

26. The composition of claim 24 wherein the transgene construct is prsGFP-MGMT/ITR.

20

27. A circularized nucleic acid construct comprising:

a nucleic acid sequence of interest flanked by a first Integrase recognition sequence and a second Integrase recognition sequence (IRS)

wherein said first IRS and second IRS are in juxtaposition to each other or are between about 2 to about 20 nucleotide bases from each other.

25

28. The circularized nucleic acid construct of claim 27 wherein the integration recognition sequences are AAV inverted terminal repeat regions or fragments thereof.

30

29. The circularized nucleic acid construct of claim 27, wherein the IRS's are LTRs or fragments thereof.

30. The circularized nucleic acid construct of claim 28, wherein the LTRs are further defined as HIV-1 sequences.
31. A method for increasing incorporation of a nucleic acid sequence of interest into
5 chromosomal nucleic acid of a cell, comprising
preparing a composition comprising a first nucleic acid sequence comprising a
transgene construct containing a nucleic acid sequence of interest flanked by
a terminal fragment of a long terminal repeat sequence; and a second nucleic
acid sequence encoding a protein capable of enhancing the incorporation of
10 the sequence of interest into the chromosomal nucleic acid of the cell.
32. The method of claim 31 wherein the second nucleic acid sequence encodes an
integration enzyme.
- 15 33. The method of claim 32 wherein the long terminal repeat sequence of the transgene
construct is further defined as a retroviral long terminal repeat sequence.
34. The method of claim 33 wherein the cell is a mammalian cell.
- 20 35. The method of claim 31 wherein the first nucleic acid sequence and the second
nucleic acid sequence are not co-extensive with one another.




Fig. 1

Possible Strategies for Integration

Anticipated Results




Fig. 2




Fig. 3




Fig. 4B

Fig. 4A




Fig. 5





Fig. 6

**Fig. 7**




Fig. 8




Fig. 9

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/24236

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12N 15/11, 15/63, 15/64

US CL : 435/172.3, 320.1; 536/23.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/172.3, 320.1; 536/23.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ---- Y	SHOJI-TANAKA et al. Gene Transfer Using Purified Retroviral Integrase. Biochemical and Biophysical Research Communications. 30 September 1994. Vol. 203. No. 3. pages 1756-1764, especially pages 1757-1758.	1-4, 8, 10-12, 15, 21-23, 27, 29-35 ----- 5-7, 9, 13-14, 16-20, 24-26, 28
Y	WO 95/32225 A1 (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES) 30 November 1995, see entire document, especially pages 4-5.	5-9, 13-14

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

26 FEBRUARY 1998

Date of mailing of the international search report

20 MAR 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer
TERRY A. MCKELVEY

Telephone No. (703) 308-0196

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, DIALOG

search terms: stable, incorporat?, long terminal repeat?, transfect?, transform?, integrase, retrovir?, DNA binding protein, GATA1, NFE2, globin, rsGFP-MGMT/LTR, MGMT/MDR-1, AAV, adeno-associated virus, rep78